Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00385138 · ClinicalTrials.gov registry record · Phase 3
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
A Phase 3 study, sponsored by The Medicines Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 5,364
- Enrollment target
NCT00385138 is a Phase 3 study that was terminated before completion, run by The Medicines Company. The registered enrollment target is 5,364 participants.
The verdict
NCT00385138, a Phase 3 study, was terminated before completion, sponsored by The Medicines Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 5,364 participants
- Enrollment target
Study Summary
The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a composite of all-cause mortality, myocardial infarction (MI), and ischemia-driven revascularization (IDR).
Interventions
- DRUG clopidogrel
- DRUG Cangrelor
- DRUG Placebo bolus & placebo infusion
- DRUG Placebo capsules - end of PCI
- DRUG Placebo capsules - end of infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,364 participants |
| Start Date | 2006-09 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00385138
The ClinicalTrials.gov registry entry for NCT00385138 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 5,364 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which clopidogrel is the first listed.
NCT00385138 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00385138 about?
NCT00385138 is a clinical study titled "Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.". The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a composite of all-cause mortality, myocardial infarction (MI), and ischemi...
What is the current status of trial NCT00385138?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5,364 participants. The study started on 2006-09. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00385138?
The interventions under investigation include: clopidogrel (DRUG), Cangrelor (DRUG), Placebo bolus & placebo infusion (DRUG), Placebo capsules - end of PCI (DRUG), Placebo capsules - end of infusion (DRUG).
Who is sponsoring clinical trial NCT00385138?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.